Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | INMT | O95050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclocreatine SCHEMBL7935371 | 0.89 | CYP2D6 (0.39) | ACEALDH1A1INMTTSHRPOLB | |
| Cyclocreatine SCHEMBL450343 | 0.89 | CYP2D6 (0.39) | ACEALDH1A1INMTTSHRPOLB | |
| Cyclocreatine SCHEMBL11796002 | 0.87 | CYP2D6 (0.38) | ACEALDH1A1INMTTSHRPOLB | |
| Cyclocreatine SCHEMBL1980714 | 0.85 | CYP2D6 (0.37) | ACEALDH1A1INMTTSHRPOLB | |
| Cyclocreatine SCHEMBL1981687 | 0.81 | INMT (0.40) | ACEINMTTSHRPOLBCYP2D6 | |
| Cyclocreatine SCHEMBL936945 | 0.78 | TSHR (0.33) | ACETSHRPOLBCYP2D6CYP2C9 | |
| SCHEMBL17234205 | 0.74 | ALDH1A1 (0.38) | ACEALDH1A1TSHRPOLBCYP2D6 | |
| SCHEMBL18528340 | 0.74 | ALDH1A1 (0.38) | ACEALDH1A1TSHRPOLBCYP2D6 | |
| SCHEMBL18528341 | 0.74 | ALDH1A1 (0.38) | ACEALDH1A1TSHRPOLBCYP2D6 | |
| Cyclocreatine SCHEMBL1980609 | 0.74 | SMN1; SMN2 (0.44) | ALDH1A1TSHRPOLBCYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373582-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | Inspirna, Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| WO-2023004308-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2023-01-26 | — | — | WO | claimed |
| WO-1994016687-A1 | USE OF CREATINE OR ANALOGS FOR THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING TUMOR GROWTH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1994-08-04 | — | — | WO | claimed |
| US-5324731-A | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated | AMIRA, INC. (US) | 1994-06-28 | — | — | US | claimed |
| EP-0557383-A1 | METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED | AMIRA, INC. (US) | 1993-09-01 | — | — | EP | claimed |
| WO-1992008456-A2 | METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED | AMIRA, INC. (US) | 1992-05-29 | — | — | WO | claimed |
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4373582-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | Inspirna, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023004308-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023004308-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-1994016712-A1 | CREATINE PHOSPHATE, CREATINE PHOSPHATE ANALOGS, AND USES THEREFOR | AMIRA, INC. (US) | 1994-08-04 | — | — | WO | disclosed |
| WO-1994016687-A1 | USE OF CREATINE OR ANALOGS FOR THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING TUMOR GROWTH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1994-08-04 | — | — | WO | disclosed |
| US-5324731-A | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated | AMIRA, INC. (US) | 1994-06-28 | — | — | US | disclosed |
| US-5321030-A | Administering for treatment or prevention | AMIRA, INC. (US) | 1994-06-14 | — | — | US | disclosed |
| EP-0557383-A1 | METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED | AMIRA, INC. (US) | 1993-09-01 | — | — | EP | disclosed |
| WO-1993012781-A2 | CREATINE ANALOGS HAVING ANTIVIRAL ACTIVITY | AMIRA, INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| WO-1992008456-A2 | METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED | AMIRA, INC. (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | ACE 1330/4885ALDH1A1 1159/4885INMT 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.